Given what is potentially at stake in this pre-eminent nosocomial infection with unacceptably high treatment failure rates, we strongly encourage a larger prospective study conducted in a blind manner to determine (i) the role of combination therapy, particularly with a β-lactam, in improving MRSA bacteremia outcomes; and (ii) employing biomarkers, such as IL-10, as potential risk stratification tools for allocating combination therapy to those at high risk. The gene discussed is IL10; the disease is nosocomial infection.